A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many years to treat plaque psoriasis and psoriatic arthritis, but it was proven to also be an effective treatment for ulcerative colitis in a global study led by UChicago Medicine’s David T. Rubin, MD, Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition. The study contributed to the FDA’s approval for its use for this disease.

Read more about this here on Newswise